LEAP2 and fatty liver disease: After knocking down LEAP-2 in mice, the expression of receptors and enzymes related to lipogenic/lipolytic metabolism was affected; as a result, liver steatosis, liver enzymes, and triglyceride content were reduced; simultaneously, proteins connected to the IRS/AKT signaling pathway were phosphorylated, resulting in improved insulin sensitivity.